Cargando…

Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients

Neoadjuvant chemotherapy (NACT) plays an important role in ovarian cancer. The appropriate time interval from the completion of NACT to interval debulking surgery (TTS) in ovarian cancer is still unknown. The aim of this retrospective study was to evaluate the effect of the time interval between the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ming, Chen, Zhanpeng, Xu, Manman, Liu, Duo, Liu, Tianyu, He, Mian, Yao, Shuzhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6218782/ https://www.ncbi.nlm.nih.gov/pubmed/30410613 http://dx.doi.org/10.7150/jca.26631

Ejemplares similares

Neoadjuvant chemotherapy in ovarian, primary peritoneal and tubal carcinoma: can imaging results prior to interval debulking predict survival?
por: Menczer, Joseph, et al.
Publicado: (2011)

Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer
por: Tate, Shinichi, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy Versus Primary Debulking Surgery in FIGO Stage III and IV Epithelial Ovarian, Tubal or Peritoneal Cancer: A Systematic Review and Meta-Analysis
por: Tzanis, Alexander A., et al.
Publicado: (2022)

Diaphragmatic Surgery and Related Complications In Primary Cytoreduction for Advanced Ovarian, Tubal, and Peritoneal Carcinoma
por: Ye, Shuang, et al.
Publicado: (2017)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Primary Ovarian Pregnancy after Interval Tubal Ligation: A Case Report
por: Vahnu, Changsan, et al.
Publicado: (2013)

Negative peritoneal washing cytology during interval debulking surgery predicts overall survival after neoadjuvant chemotherapy for ovarian cancer
por: Iura, Ayaka, et al.
Publicado: (2018)

Outcomes in Advanced Stage Epithelial Ovarian, Fallopian Tubal, and Peritoneal Cancer after Primary Surgery and Adjuvant Chemotherapies: A Single-Institute Real-World Experience
por: Chang, Chia-Hua, et al.
Publicado: (2020)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
por: Zhang, Yuedi, et al.
Publicado: (2022)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma
por: Hegazy, Mohamed AF, et al.
Publicado: (2005)

Second primary cancer after primary peritoneal, epithelial ovarian, and fallopian tubal cancer: a retrospective study
por: Lim, Myong Cheol, et al.
Publicado: (2018)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Primary high-grade serous cancer arising from uterosacral ligament endometriosis: two case reports
por: Chen, Ming, et al.
Publicado: (2022)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers
por: Jeon, Seob, et al.
Publicado: (2017)

Comparison of secondary cytoreductive surgery plus chemotherapy with chemotherapy alone for recurrent epithelial ovarian, tubal, or peritoneal carcinoma: A propensity score-matched analysis of 112 consecutive patients
por: Takahashi, Akimasa, et al.
Publicado: (2017)

The Diagnosis and Treatment of Acute Tubal Peritonitis
por: Struthers, J. W.
Publicado: (1922)

The efficacy of secondary cytoreductive surgery for recurrent ovarian, tubal, or peritoneal cancer in Tian-model low-risk patients
por: So, Makiko, et al.
Publicado: (2019)

Role of Lymphadenectomy During Interval Debulking Surgery Performed After Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
por: He, Minjun, et al.
Publicado: (2021)

Impact of prehabilitation during neoadjuvant chemotherapy and interval cytoreductive surgery on ovarian cancer patients: a pilot study
por: Miralpeix, Ester, et al.
Publicado: (2022)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
por: Wu, Pei-Ying, et al.
Publicado: (2020)

Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery
por: Wan, Xiang-Bo, et al.
Publicado: (2020)

A Single-Center, Retrospective Study of Bevacizumab-Containing Neoadjuvant Chemotherapy followed by Interval Debulking Surgery for Ovarian Cancer
por: Park, Junsik, et al.
Publicado: (2020)

Potential Role of Semaphorin 3A and Its Receptors in Regulating Aberrant Sympathetic Innervation in Peritoneal and Deep Infiltrating Endometriosis
por: Liang, Yanchun, et al.
Publicado: (2015)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
por: Liang, Wei-feng, et al.
Publicado: (2021)

Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort
por: Feng, Zheng, et al.
Publicado: (2021)

LEF1 is preferentially expressed in the tubal-peritoneal junctions and is a reliable marker of tubal intraepithelial lesions
por: Schmoeckel, Elisa, et al.
Publicado: (2017)

Neoadjuvant chemotherapy or primary surgery for stage III/IV ovarian cancer: contribution of diagnostic laparoscopy
por: Brun, Jean-Luc, et al.
Publicado: (2009)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer
por: Liu, Xiao-Dong, et al.
Publicado: (2018)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Interval debulking surgery is not worth the wait: a National Cancer Database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy
por: Lyons, Yasmin A, et al.
Publicado: (2020)

Neoadjuvant Chemotherapy plus Interval Cytoreductive Surgery with or without Hyperthermic Intraperitoneal Chemotherapy (NIHIPEC) in the Treatment of Advanced Ovarian Cancer: A Multicentric Propensity Score Study
por: Llueca, Antoni, et al.
Publicado: (2023)

Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept
por: Jiang, Rong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h2d9e031mhbradmjjl3od156di